How GLP-1 Medications Actually Work

GLP-1: the hormone your body already makes

GLP-1 stands for glucagon-like peptide-1. It is a hormone your small intestine releases in response to eating, and it has been part of normal human physiology for as long as humans have existed. The drugs that get so much attention — Ozempic, Wegovy, Mounjaro, Foundayo — are designed to imitate this hormone, not to introduce something foreign.

When you eat, specialized cells in your small intestine called L-cells detect the incoming food. They respond by releasing GLP-1 into your bloodstream. The hormone travels to several places and does several things:

• In the pancreas, it tells beta cells to release insulin in response to rising blood sugar — but only when blood sugar is actually rising. This glucose-dependent insulin release is why GLP-1-based drugs rarely cause low blood sugar on their own.
• In the liver, it reduces glucagon release, which in turn reduces the amount of glucose the liver dumps into circulation.
• In the stomach, it slows how quickly the stomach empties into the small intestine. Food stays in the stomach longer.
• In the brain, it signals satiety — the feeling of being full — and reduces the reward signals that normally follow eating.

That last effect is the one that explains the "food noise goes quiet" experience people describe on GLP-1 medications. The constant background thought about what to eat next, which many people with obesity live with, is modulated by brain reward circuits that respond to GLP-1 signaling.

The problem with the natural hormone

Natural GLP-1 has a fatal flaw as a drug candidate: your body destroys it almost instantly. The hormone has a half-life of roughly two minutes in the bloodstream before an enzyme called DPP-4 (dipeptidyl peptidase-4) breaks it down. That is useful biologically — you do not want meal-related satiety signals lingering for hours — but it is catastrophic pharmaceutically. You would need to inject natural GLP-1 every few minutes to maintain any meaningful therapeutic effect.

The entire history of GLP-1 drug development is, at its core, about solving this durability problem. How do you create a molecule that engages the GLP-1 receptor the same way the natural hormone does but survives in the body long enough to actually do something useful?

What a GLP-1 receptor agonist actually does

The medications in this class are called GLP-1 receptor agonists. "Agonist" is pharmacology jargon for "a molecule that binds to a receptor and activates it the way the natural signal would." A GLP-1 receptor agonist locks onto the GLP-1 receptor and tells the cell to do what it would do if natural GLP-1 were attached — release insulin, slow gastric emptying, signal satiety.

The trick was designing agonists that (a) bind the receptor as effectively as natural GLP-1 and (b) resist DPP-4 breakdown. The solution turned out to be modifying the peptide sequence in ways that preserved receptor-binding but changed the shape just enough that DPP-4 could not grab hold of it.

Semaglutide, for example, is a modified version of native GLP-1 with two key changes: a tweak to one amino acid that DPP-4 normally targets, and a fatty acid chain attached that makes the molecule stick to albumin (a blood protein) and travel through the bloodstream slowly. These modifications extend semaglutide's half-life from ~2 minutes (natural GLP-1) to roughly 7 days (why Ozempic and Wegovy are weekly injections).

Tirzepatide is a different story — it activates both the GLP-1 receptor and the GIP receptor (a related gut hormone receptor). That dual mechanism is why tirzepatide-based drugs (Mounjaro, Zepbound) produce more weight loss than semaglutide-based drugs in head-to-head comparison.

The three classes of GLP-1 drug

As of 2026, the GLP-1 class can be organized into three categories based on how the molecule is delivered and what it is made of:

Each class has trade-offs. Injectable peptides deliver the most complete drug-like exposure (100% of the injected dose enters circulation) and produce the strongest weight loss. Oral peptides solve the needle problem but pay a steep price in bioavailability and require a fasting protocol. Oral small molecules are a newer approach with less weight loss but dramatically better convenience.

Why oral peptide GLP-1s are so hard

If you could just put a peptide GLP-1 in a pill and have it work, the oral version would have launched years before the injectable version. Instead, oral semaglutide (Rybelsus) required a decade of formulation research to become viable as a once-daily tablet. The challenges are specific and unavoidable if your molecule is a peptide:

1. Stomach acid

Your stomach is, by design, a hostile environment for proteins. Stomach acid (gastric pH around 1–2) denatures most peptides. Digestive enzymes like pepsin then break them into smaller and smaller pieces. A peptide swallowed as a pill, with no protection, would be largely destroyed before it ever left the stomach.

2. The intestinal barrier

Even if a peptide survives the stomach, it has to cross the intestinal lining to enter the bloodstream. That lining is evolutionarily designed to let small molecules (nutrients, most drugs) through while blocking large ones (proteins, pathogens, antigens). Semaglutide is a large molecule. Without an absorption enhancer, essentially none of it gets through.

3. The SNAC solution and its costs

Novo Nordisk solved both problems with a co-formulation: semaglutide paired with SNAC (salcaprozate sodium), an absorption enhancer that temporarily disrupts the stomach lining in a small localized area around each tablet. SNAC creates a brief absorption window where the semaglutide can pass into circulation before the disruption closes.

This works — but with caveats:

• Bioavailability is still only 0.4–1%. Most of the drug you swallow never reaches the bloodstream. This is why oral doses (7 mg, 14 mg, 25 mg) look so much larger than injectable doses (0.25 mg, 1 mg).
• Food or even normal water intake ruins it. If there is anything in the stomach, the absorption window does not open effectively. Hence the empty-stomach + 30-minute wait protocol.
• Patient-to-patient variability is significant. Some people absorb more, some less, and the same person may absorb differently on different days.

SNAC is a clever engineering solution to a fundamental mismatch between peptides and pills. It works, but it does not fix the underlying problem — it works around it.

The small-molecule breakthrough

The alternative approach is to give up on peptides for oral GLP-1 entirely and design a completely different kind of molecule that binds the same receptor. That is what orforglipron (Foundayo) is — a small-molecule GLP-1 receptor agonist that is roughly one-tenth the mass of semaglutide and is not a peptide at all.

Orforglipron was discovered at Chugai Pharmaceutical in Japan and licensed to Eli Lilly in 2018. Finding a small molecule that binds the GLP-1 receptor effectively was the hard scientific challenge — the GLP-1 receptor is a large, complex protein that evolved to bind another large complex protein (the natural hormone), and finding a small non-peptide partner that fits into the binding pocket was not obvious.

Once the molecule was identified, though, the downstream advantages stacked up quickly:

• No stomach acid problem. Small molecules are stable at gastric pH.
• No intestinal barrier problem. Small molecules diffuse through the intestinal lining the way most oral drugs do.
• No absorption enhancer needed. Without SNAC, no fasting protocol.
• Cheap and simple to manufacture at scale. Small molecules are made by traditional pharmaceutical chemistry, not the specialized peptide synthesis that peptide drugs require.

The trade-off is that orforglipron, at least in its current form, is not quite as potent as injectable semaglutide or tirzepatide. Weight loss in the ATTAIN-1 trial reached about 11.2% at 72 weeks versus 15% for injectable semaglutide and ~21% for injectable tirzepatide. But in the oral category, orforglipron leads — and it does so without requiring any fasting compromise.

Why the side effects happen

Understanding the side effect profile of GLP-1 drugs is easier once you understand what they do mechanistically. The common side effects are not random toxicities — they are direct consequences of how the drugs engage their target.

Gastrointestinal side effects

Nausea, vomiting, constipation, diarrhea, and abdominal discomfort are the most common side effects of every GLP-1 drug. They happen because GLP-1 slows gastric emptying by design. Food staying in the stomach longer is part of the satiety mechanism, but it is also how nausea and indigestion happen. The body generally adapts to this effect over weeks to months, which is why titration schedules (starting at low doses and stepping up gradually) are standard — they give your digestive system time to acclimate.

Why titration matters

Going too quickly from zero to a high dose is the single most common cause of severe side effects and discontinuation. The stepwise titration schedules on all GLP-1 medications exist for a reason: your digestive system needs time to adjust at each dose level before moving up. Skipping a step or compressing the timeline is almost guaranteed to cause more side effects than you would otherwise experience.

Pancreatitis and thyroid cancer warnings

All GLP-1 drugs carry a boxed warning for thyroid C-cell tumors based on rodent studies. The actual human risk is not well-established and the warning is class-wide rather than drug-specific. Pancreatitis has been reported in small numbers across GLP-1 trials — the causal link is debated, but persistent severe abdominal pain on any GLP-1 should be evaluated medically.

Hypoglycemia

Low blood sugar is uncommon with GLP-1 drugs on their own because the drugs only stimulate insulin release when blood sugar is rising. If you are on a GLP-1 and also taking insulin or a sulfonylurea, the combination can cause hypoglycemia and dose adjustments are usually needed.

Why this matters for choosing a medication

The mechanism-level understanding helps explain why the choice of GLP-1 is not interchangeable. Injectable tirzepatide produces more weight loss because it engages two receptors instead of one. The Wegovy pill produces slightly more weight loss than Foundayo because peptide receptor engagement appears to be more complete than small-molecule engagement at current doses. But the Wegovy pill's fasting requirement is what makes many real-world patients either skip doses or take them incorrectly — which erases much of the trial advantage.